selekoa

A documentary history of machine intelligence.

Records found and checked by machines, not reviewed by an editor · What this means →

Record explorer

Explore the documentary record

Every claim links to its source passage,
its dates where known and its limits.

Institutional dossier

Ailux

Built from the same claims and evidence as the map.

Institutional dossier

The documented history of Ailux: chronology, people, research, capital and compute, and governance. Every statement opens its source and its limits.

Records dated 2025-11-05 to 2025-11-05 · 0 undated

1 claims · 1 sources · 1 not editorially accepted. The counts describe this selection. They do not measure completeness or independent confirmation.

Scope, evidence and limits

Description: XtalPi's biologics arm (Ailux Holdings Limited and its subsidiary Shanghai Ailux Biotechnology Co., Ltd.), as XtalPi describes it.

The records are grouped automatically. No human inspection of the selected claims, source paths or framing is recorded for this dossier. Each source passage shows how it was checked.

The dossier is computed from existing records. It is not a continuous history of the institution, and a missing record does not mean that an event or relationship did not happen. The chronology uses the dates of events and reports, not the date the public could first have known of them. Later sources can describe earlier events.

Select any statement to see its exact claim, qualification, date note, evidence passage, location in the source, source version and review status. The description above is Selekoa’s stored description of the institution, based on these sources:

Chronology

Records about the institution itself and documented changes to its frameworks, by year. Expand a year to read the claims. People’s other institutional records and related documents have their own sections. Where a date gives only the year or month, the order within it is unknown.

2025Record year · 1 claims
  1. 2025-11-05 · announcementinstitutions
    XtalPi announced on 5 November 2025 that its wholly-owned subsidiary Shanghai Ailux Biotechnology entered a strategic platform-based collaboration with Eli Lilly and Company on bispecific antibodies, with a total potential value of up to US$345 million.Ailux → announced a partnership with → Eli Lilly and CompanyInspect claim & evidence ↗

    Record about this institution · Stated in source · Supported Announced

    Activity: announced

    Qualification and date notes

    Announced terms as XtalPi states them; "up to" is conditional on milestones and is not a payment. The upfront and near-term amounts are stated only as "tens of millions US dollars".

    Date of the HKEXnews listing of XtalPi's announcement.